E-GEOD-46307 - In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling
Released on 24 April 2013, last updated on 3 June 2014
Primary leukemia stem cells (LSCs) reside in an in vivo microenvironment that supports the growth and survival of malignant cells. We used an in vivo short hairpin RNA (shRNA) screening approach to identify novel genes that are essential for primary murine MLL-AF9 acute myeloid leukemia (AML). We found that Integrin Beta 3 (Itgb3) is selectively essential for murine leukemia cells in vivo, and for human leukemia cells in xenotransplantation studies. In leukemia cells, Itgb3 knockdown impaired homing, downregulated LSC transcriptional programs, and induced differentiation. In contrast, loss of Itgb3 in normal HSPCs did not affect engraftment, reconstitution, or differentiation in long term transplantation assays. We explored the signaling pathways downstream of Itgb3 using an additional in vivo shRNA screen and identified Syk as a critical mediator of Itgb3 activity in leukemia. Finally, we confirmed that Itgb3 is dispensable for normal hematopoiesis and required for leukemogenesis using the Itgb3 knockout mouse model. Our results establish the significance of the Itgb3 signaling pathway as a potential therapeutic target in AML, and demonstrate the utility of in vivo RNA interference screens. We examined the effect of Itgb3 knockdown by gene expression profiling in primary leukemia cells.
transcription profiling by array
Fatima Al-Shahrour <email@example.com>, Alexandre Puissant, Benjamin L Ebert, Christopher A Shelton, Craig T Jordan, David E Root, David T Scadden, Glenn S Cowley, John Ashton, Joji Fujisaki, Kevin P Callahan, Kimberly A Hartwell, Kimberly Stegmaier, Lev Silberstein, Lisa P Chu, Luke P Poveromo, Marcus Järås, Marie E McConkey, Michael G Kharas, Muhammad A Al-Hajj, Myriam Labelle, Peter G Miller, Richard O Hynes, Rishi V Puram, Scott A Armstrong, Sebastian Shterental, Siddhartha Mukherjee